Guidance for Industry on Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the Federal Food, Drug, and Cosmetic Act
ICR 201409-0910-002
OMB: 0910-0776
Federal Form Document
⚠️ Notice: This information collection may be outdated. More recent filings for OMB 0910-0776 can be found here:
Guidance for Industry on Fees
for Human Drug Compounding Outsourcing Facilities Under Sections
503B and 744K of the Federal Food, Drug, and Cosmetic Act
New
collection (Request for a new OMB Control Number)
Once an entity has elected to register
as an outsourcing facility, it must pay certain fees to be
registered as an outsourcing facility. The guidance describes the
types and amounts of fees that outsourcing facilities must pay, the
adjustments to fees required by law, how outsourcing facilities may
submit payment to FDA, the consequences of outsourcing facilities'
failure to pay fees, and how an outsourcing facility may qualify as
a small business to obtain a reduction in fees
US Code:
21
USC 355 Name of Law: Federal Food, Drug, and Cosmetic Act
US Code:
21 USC 352(F)(1) Name of Law: FD&C Act
Ila Mizrachi 301 796-7726
ila.mizrachi@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.